



RNS Number : 8960A
Roquefort Therapeutics PLC
28 September 2022

28 September 2022

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Stephen West, Executive Chairman and Dr Simon Sinclair, a Non-Executive Director have purchased ordinary shares in the Company in the market, as detailed below:

Name	Number of Ordinary Shares	Average Price Paid Per Share	Total Consideration Paid
Stephen West	244,656	8.175 pence	£19,999.79
Simon Sinclair	60,415	8.276 pence	£4,999.97

Following the above purchase of shares, Stephen West and Simon Sinclair hold interests in the following Company securities:

Name	Number of Ordinary Shares Held	% of Issued Share Capital	Number of Warrants Held
Stephen West	5,313,264	4.11%	7,500,000
Simon Sinclair	60,415	0.05%	300,000

4,628,485 of Mr West's shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) / Ajan Reginald
(CEO) +44 (0)20 3290
9339

Hybridan LLP (Joint Broker)

Claire Louise Noyce +44 (0)203 764
2341

Optiva Securities Limited (Joint Broker)

Christian Dennis +44 (0)20 3411
1881

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale
+44 (0)20 7466
5000

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- MK cell therapy with direct and NK-mediated anti-cancer action; and
- siRNA targeting novel STAT-6 target in solid tumours showing significant *in vivo* efficacy.

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Stephen West	
2	Reason for the notification		
a)	Position/status	Executive Chairman	
b)	Initial notification /Amendment	Initial	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Roquefort Therapeutics plc	
b)	LEI	254900P4SISIWOR9RH34	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.01 par value	
	Identification code	ISIN: GB00BMDQ2T15	
b)	Nature of the transaction	Purchase of 244,656 ordinary shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		8.000 pence per share	62,040
		8.215 pence per share	60,416
		8.000 pence per share	62,040
		8.250 pence per share	60,160
d	Aggregated information		
	- Aggregated volume	-	244,656
	- Price	-	8.175p
e)	Date of the transactions	27 September 2022	
f)	Place of the transactions	London Stock Exchange (XLON); Main Market	

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr Simon Sinclair	
2	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Roquefort Therapeutics plc	
b)	LEI	254900P4SISIWOR9RH34	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.01 par value	
	Identification code	ISIN: GB00BMDQ2T15	
b)	Nature of the transaction	Purchase of 60,415 ordinary shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		8.276 pence per share	60,415

d	Aggregated information	
	- Aggregated volume	- 60,415
	- Price	- 8.276p
e)	Date of the transactions	27 September 2022
f)	Place of the transactions	London Stock Exchange (XLON); Main Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBLGDCGGDDGDR
 Anonymous (not verified)
 Director/PDMR Shareholding
 32992614
 A
 Wed, 09/28/2022 - 07:00
 LSE RNS
 Directors' Dealings
 ROQ